Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q0OR
|
||||
Former ID |
DIB020990
|
||||
Drug Name |
SSR126768A
|
||||
Synonyms |
SSR-126768A
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C33H31Cl2N3O4
|
||||
InChI |
InChI=1S/C33H31Cl2N3O4/c1-5-37(19-21-7-6-14-36-18-21)31(39)22-9-12-28(35)26(15-22)33(2)27-16-24(34)10-13-29(27)38(32(33)40)20-23-8-11-25(41-3)17-30(23)42-4/h6-18H,5,19-20H2,1-4H3/t33-/m0/s1
|
||||
InChIKey |
UENRBNCNIZQNTR-XIFFEERXSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Vasopressin V1a receptor | Target Info | Antagonist | [2] | |
Oxytocin receptor | Target Info | Antagonist | [2] | ||
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Vascular smooth muscle contractionhsa04020:Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
Oxytocin signaling pathway | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
Reactome | Vasopressin-like receptors | ||||
G alpha (q) signalling eventsR-HSA-388479:Vasopressin-like receptors | |||||
G alpha (q) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
Myometrial Relaxation and Contraction Pathways | |||||
Oxytocin signaling | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2201). | ||||
REF 2 | SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. Epub 2004 Jan 13. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.